ClinicalTrials.gg
RecruitingNCT07537998Updated Apr 17, 2026

Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial.

A Phase 2/3 interventional study of intestinal fluid infusion and potable water in Low Anterior Resection Syndrome and Rectal Cancer, sponsored by Pei-Rong Ding. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Pei-Rong Ding · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Low Anterior Resection Syndrome with a site in China — 7 open to participants now, 9 under way, 1 of them phase 3. Low Anterior Resection Syndrome · China.

Planned enrollment
4th of 10
160 · median 146
Started
2026
with 1 other
Phase 2/3
Only one
of the 13
Registered
11th of 13
by date
Lead sponsor
1 of 13
Pei-Rong Ding

Among the 13 studies in Low Anterior Resection Syndrome with a site in China, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 2/3, and was the 11th registered.

Low Anterior Resection Syndrome

82 studies on the registry are indexed under Low Anterior Resection Syndrome; 38 are open to participants now.

Browse Low Anterior Resection Syndrome studies →

Open to participants now

7 of the 13 studies in Low Anterior Resection Syndrome with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Low Anterior Resection Syndrome studies recruiting now, 17 (68%) set no upper age limit and 4 (16%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Low Anterior Resection Syndrome with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if antegrade intestinal fluid reinfusion works to prevent low anterior resection syndrome (LARS) in patients with prophylactic ileal stoma. The main questions it aims to answer are:

  1. Does it work to prevent LARS by antegrade intestinal fluid reinfusion before performing the ileostomy reversal surgery?
  2. Is antegrade intestinal fluid reinfusion more effective than water infusion in preventing LARS.

Participants will:

  1. Receive either antegrade intestinal fluid reinfusion or antegrade water infusion through ileal stoma based on the standard of care at 1 month after anterior rectal resection, until the ileostomy reversal.
  2. Keep a diary of their symptoms.
03

Conditions studied

  • Low Anterior Resection Syndrome
  • Rectal Cancer

Keywords

  • low anterior resection syndrome
  • antegrade intestinal fluid reinfusion
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with mid to low rectal cancer (within 10cm of the anal verge) who undergo radical DIXON+ileostomy surgery.
  • General situation is well and one can take care of themselves.
  • Anal digital examination confirms that the anastomotic site has fully healed 1 month after surgery.
  • The anal sphincter function is good, and the ilestomy reverse surgery has not been completed.
  • Regardless of whether preoperative radiotherapy or chemotherapy has been received.

Exclusion criteria

Exclusion Criteria:

  • Patients with anastomotic leakage after rectal cancer surgery.
  • The patient's general physical condition is poor and they are unable to take care of themselves.
  • Expected inability to retract the stoma.
  • Patients with preoperative inflammatory bowel disease, such as ulcerative colitis, Crohn's disease, etc.
  • inability to treat according to the plan, poor compliance.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Intestinal fluid reinfusion

    Starting from 4 weeks after the DIXON + ileostomy surgery until the day before the ileostomy reversal surgery, the patient was instructed on enema procedures by enterostomal therapist after being enrolled in the study. After preparing the autologous intestinal fluid, it is diluted with warm saline to a volume of 200-500 ml. It is then returned through the distal end of the ileal stoma in a retrograde manner, once every other day.

    Combination Product: intestinal fluid infusion

  • Active comparator
    Water infusion

    Starting from 4 weeks after the DIXON + ileostomy surgery until the day before the ileostomy reversal surgery, the patient was instructed on enema procedures by enterostomal therapist after being enrolled in the study. Prepare 200-500 ml of potable water, and then infuse it antegradely from the distal end of the ileal stoma, once every other day.

    Combination Product: potable water

Interventions

  • Combination productintestinal fluid infusion

    Prepare autologous intestinal fluid and perform rantegrade reinfusion from the distal end of the stoma.

  • Combination productpotable water

    Infuse potable water through the distal end of the stoma.

06

What researchers measure

Primary outcomes

  1. LARS score(m1)

    Improvement in LARS score 1 month after ileostomy reversal surgery between the two group. Low Anterior Resection Syndrome Score (LARS Score) is a validated specific score for low anterior resection syndrome which ranges from 0 points (normal - best score) to 42 point (LARS major - worst score).

    Time frame: 1 month after ileostomy reversal surgery

Secondary outcomes

  1. Major LARS rate(m1)

    Major LARS rate 1 month after ileostomy reversal

    Time frame: 1 month after ileostomy reversal

  2. LARS score (m0-12)

    Trajectory of change of LARS score after ileostomy reversal surgery in the two group. Low Anterior Resection Syndrome Score (LARS Score) is a validated specific score for low anterior resection syndrome which ranges from 0 points (normal - best score) to 42 point (LARS major - worst score).

    Time frame: 2 weeks, 1 month, 2 months, 3 months, 6 months and 12 months after ileostomy reversal surgery

  3. MSKCC BFI

    Memorial Sloan Kettering Cancer Centre Bowel Function Instrument

    Time frame: 2 weeks, 1 month, 2 months, 3 months, 6 months and 12 months after ileostomy reversal surgery

  4. Wexner score

    The Wexner scoring system is a clinical tool used to assess the severity of constipation. Mainly used to quantify the constipation symptoms of patients and their impact on their quality of life. Including five aspects: defecation frequency, difficulty in defecation, emptying sensation, abdominal pain, and time spent in the toilet. The total score range is 0-25 points. A score below 7 points is considered mild constipation, 7-15 points is moderate constipation, and above 15 points is severe constipation.

    Time frame: 2 weeks, 1 month, 2 months, 3 months, 6 months and 12 months after ileostomy reversal surgery

  5. quality of life for rectal cancer patients

    quality of life will be measured using the EORTC Colorectal Cancer Module QLQ-CR29 (EORTC QLQ-CR29 )

    Time frame: 2 weeks, 1 month, 2 months, 3 months, 6 months and 12 months after ileostomy reversal surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2026
First posted
Apr 17, 2026
StartEst.
Apr 10, 2026
Primary completionEst.
Apr 10, 2027
CompletionEst.
Apr 10, 2028
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07537998
Lead sponsor
Pei-Rong Ding
Responsible party
Pei-Rong Ding (Professor, Sun Yat-sen University) — Sponsor-investigator
First posted
Apr 17, 2026
Start date
Apr 10, 2026 (estimated)
Primary completion
Apr 10, 2027 (estimated)
Completion
Apr 10, 2028 (estimated)
Last update
Apr 17, 2026

Study contacts

Peirong Ding, M.D
Contact
dingpr@sysucc.org.cn
86-020-87343920

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion